Souders Financial Advisors Sells 434 Shares of Alnylam Pharmaceuticals, Inc. $ALNY

Souders Financial Advisors cut its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 24.2% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,359 shares of the biopharmaceutical company’s stock after selling 434 shares during the quarter. Souders Financial Advisors’ holdings in Alnylam Pharmaceuticals were worth $443,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also bought and sold shares of the company. Bayforest Capital Ltd grew its holdings in shares of Alnylam Pharmaceuticals by 14.6% in the first quarter. Bayforest Capital Ltd now owns 306 shares of the biopharmaceutical company’s stock worth $83,000 after purchasing an additional 39 shares during the last quarter. Fulton Bank N.A. boosted its position in Alnylam Pharmaceuticals by 3.3% during the 2nd quarter. Fulton Bank N.A. now owns 1,421 shares of the biopharmaceutical company’s stock valued at $463,000 after buying an additional 46 shares during the period. Northwestern Mutual Wealth Management Co. grew its holdings in Alnylam Pharmaceuticals by 10.3% in the 1st quarter. Northwestern Mutual Wealth Management Co. now owns 525 shares of the biopharmaceutical company’s stock worth $142,000 after acquiring an additional 49 shares during the last quarter. Edmond DE Rothschild Holding S.A. increased its position in shares of Alnylam Pharmaceuticals by 18.2% in the first quarter. Edmond DE Rothschild Holding S.A. now owns 318 shares of the biopharmaceutical company’s stock valued at $86,000 after acquiring an additional 49 shares during the period. Finally, Lindbrook Capital LLC raised its stake in shares of Alnylam Pharmaceuticals by 9.2% during the first quarter. Lindbrook Capital LLC now owns 596 shares of the biopharmaceutical company’s stock valued at $161,000 after acquiring an additional 50 shares during the last quarter. 92.97% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on ALNY. Citigroup boosted their price target on Alnylam Pharmaceuticals from $527.00 to $583.00 and gave the company a “buy” rating in a report on Tuesday, September 2nd. Needham & Company LLC raised their price target on Alnylam Pharmaceuticals from $377.00 to $478.00 and gave the stock a “buy” rating in a research note on Thursday, July 31st. Barclays upped their price objective on shares of Alnylam Pharmaceuticals from $460.00 to $527.00 and gave the stock an “overweight” rating in a report on Friday, October 31st. Weiss Ratings reissued a “sell (d-)” rating on shares of Alnylam Pharmaceuticals in a research note on Wednesday, October 8th. Finally, Piper Sandler restated an “overweight” rating and issued a $489.00 price objective (up from $449.00) on shares of Alnylam Pharmaceuticals in a report on Friday, October 31st. Twenty-three equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Alnylam Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $478.67.

Alnylam Pharmaceuticals Price Performance

Shares of NASDAQ:ALNY opened at $440.49 on Friday. The business has a fifty day moving average price of $458.82 and a 200-day moving average price of $374.54. The company has a market capitalization of $58.19 billion, a PE ratio of -178.34 and a beta of 0.30. Alnylam Pharmaceuticals, Inc. has a 1-year low of $205.87 and a 1-year high of $495.55. The company has a debt-to-equity ratio of 4.10, a current ratio of 2.80 and a quick ratio of 2.75.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $2.90 earnings per share for the quarter, topping analysts’ consensus estimates of $1.39 by $1.51. The company had revenue of $1.25 billion during the quarter, compared to analyst estimates of $943.37 million. Alnylam Pharmaceuticals had a negative net margin of 12.96% and a negative return on equity of 273.52%. The firm’s revenue for the quarter was up 149.3% on a year-over-year basis. During the same period in the previous year, the business earned ($0.50) EPS. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, equities analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Insider Activity

In related news, Director Colleen F. Reitan sold 18,000 shares of the stock in a transaction on Tuesday, September 9th. The stock was sold at an average price of $467.60, for a total transaction of $8,416,800.00. Following the sale, the director directly owned 775 shares of the company’s stock, valued at $362,390. This trade represents a 95.87% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Jeffrey V. Poulton sold 3,821 shares of the company’s stock in a transaction dated Thursday, October 2nd. The shares were sold at an average price of $452.05, for a total transaction of $1,727,283.05. Following the transaction, the executive vice president owned 54,052 shares in the company, valued at $24,434,206.60. This represents a 6.60% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 98,144 shares of company stock valued at $44,160,261. Corporate insiders own 1.50% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.